NASDAQ
27.07USD
-1.93 (-6.66%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.4B
P/E
—
EPS
—
Beta
1.13
52W range
6.25-34.39
Day range
26.75–29.23
Open
28.71
Prev close
29.00
Volume
3.2M
Avg volume
4M
Dividend
0.00
IPO
2020-09-03
https://www.defenseworld.net/2026/07/19/tango-therapeutics-nasdaqtngx-trading-up-6-1-should-you-buy.html · 7/19/2026+0.60
https://www.defenseworld.net/2026/07/19/copeland-capital-management-llc-purchases-shares-of-87149-ares-management-corporation-ares.html · 7/19/2026+0.30
https://www.zacks.com/stock/news/2947086/is-tngx-stock-still-worth-buying-after-its-huge-rally-in-2026?cid=CS-STOCKNEWSAPI-FT-analyst_blog_plus|zer_report_insights-2947086 · 7/2/2026+0.40
https://www.zacks.com/stock/news/2947081/tngx-stock-outlook-hinges-on-vopimetostat-and-key-2026-catalysts?cid=CS-STOCKNEWSAPI-FT-analyst_blog_plus|zer_report_insights-2947081 · 7/2/2026+0.40
https://www.globenewswire.com/news-release/2026/06/10/3309430/0/en/Tango-Therapeutics-Announces-Pricing-of-600-Million-Upsized-Public-Offering.html · 6/10/2026
https://seekingalpha.com/article/4879634-tango-therapeutics-im-not-buying-into-latest-rally-despite-prmt5-promise · 3/6/2026-0.20
https://www.investors.com/news/technology/tango-therapeutics-erasca-deal-biotech-stock/ · 3/5/2026+1.00
https://www.globenewswire.com/news-release/2025/08/26/3139116/0/en/Tango-Therapeutics-to-Participate-in-the-2025-Cantor-Global-Healthcare-Conference.html · 8/26/2025+0.10
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
